Galectin-3 favours tumour metastasis via the activation of β-catenin signalling in hepatocellular carcinoma

Abstract

The Galectin-3-β-catenin-IGFBP3/vimentin signalling cascade was determined as a central mechanism controlling HCC metastasis, providing possible biomarkers for predicating vascular metastasis and sorafenib resistance, as well as potential therapeutic targets for the treatment of HCC patients.